Tao Liu Acquires 19.9% Stake in China Pharma Holdings (CPHI)

TL;DR

**Tao Liu just bought 19.9% of China Pharma Holdings, making him a huge player.**

AI Summary

Tao Liu, a Chinese individual, has reported beneficial ownership of 15,000,000 shares of China Pharma Holdings, Inc. (CPHI) common stock as of December 28, 2023. This represents a significant 19.9% stake in the company, making Liu a major shareholder. This matters to investors because a large individual stake can signal confidence in the company's future, but also means a single person holds substantial voting power, potentially influencing corporate decisions.

Why It Matters

This filing reveals a new significant shareholder, Tao Liu, who now controls nearly 20% of China Pharma Holdings, giving him considerable influence over the company's direction.

Risk Assessment

Risk Level: medium — While a large stake can signal confidence, it also concentrates voting power, which could lead to decisions favoring the major shareholder over other investors.

Analyst Insight

Investors should monitor future filings from Tao Liu (e.g., 13D if he changes intent) and any corporate announcements from China Pharma Holdings regarding board composition or strategic direction, as a 19.9% stake grants significant influence.

Key Numbers

• 15,000,000 — Shares Beneficially Owned (Represents the total shares Tao Liu has sole voting and dispositive power over.)
• 19.9% — Percentage of Class (Indicates the significant ownership stake Tao Liu holds in China Pharma Holdings, Inc.)
• December 28, 2023 — Event Date (The specific date that triggered the requirement for this SC 13G filing.)

Key Players & Entities

• Tao Liu (person) — reporting person and beneficial owner
• China Pharma Holdings, Inc. (company) — issuer of the securities
• 15,000,000 (dollar_amount) — shares beneficially owned
• 19.9% (dollar_amount) — percentage of class beneficially owned
• December 28, 2023 (date) — date of event requiring filing

Forward-Looking Statements

• Tao Liu will likely seek a board seat or increased influence in China Pharma Holdings given his significant stake. (Tao Liu) — medium confidence, target: Within 6-12 months
• The stock price of China Pharma Holdings may see short-term volatility as investors react to the news of a new major shareholder. (China Pharma Holdings, Inc.) — medium confidence, target: Within 1-3 weeks

FAQ

Key Financial Figures

• $0.001 — Inc. (Name of Issuer) Common stock, $0.001 par value (Title of Class of Securiti

Filing Documents

• ea192293-13gliu_china.htm (SC 13G) — 49KB
• 0001213900-24-007039.txt ( ) — 51KB

From the Filing

SC 13G 1 ea192293-13gliu_china.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* China Pharma Holdings, Inc. (Name of Issuer) Common stock, $0.001 par value (Title of Class of Securities) 16941T203 (CUSIP Number) December 28, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise CUSIP No. 16941T203 1 NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Tao Liu 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) (b) 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION China NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: 5 SOLE VOTING POWER 15,000,000 6 SHARED VOTING POWER 0 7 SOLE DISPOSITIVE POWER 15,000,000 8 SHARED DISPOSITIVE POWER 0 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 15,000,000 10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 27.3% 12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) IN FOOTNOTES * Reporting Person Tao Liu received the number shares as indicated in Row (9) through a technology transfer agreement with Hainan Helpson Medical & Biotechnology Co., Ltd (“Helpson”), a wholly owned subsidiary of China Pharma Holdings, Inc. (the “Issuer”). A copy of which will be filed as an exhibit in the Issuer’s annual report on Form 10-K for the fiscal year ended December 31, 2023. The number of shares of the Issuer’s common stock owned by Tao Liu as of the date of this filing was 15,000,000 shares, which is 27.29% of the 54,967,822 shares outstanding on January 23, 2024. 2 Item 1. (a) Name of Issuer China Pharma Holdings, Inc. (b) Address of Issuer’s Principal Executive Offices 2nd Floor No. 17 Jinpan Rd. Hainan Province 570216 China Item 2. (a) Name of Person Filing Tao Liu (b) Address of Principal Business Office or, if none, Residence No. 9, Unit 3, Building 3 Labor People’s New Village No.16, Shierqiao Road Qingyang District, Chengdu City, 610032, China (c) Citizenship China (d) Title of Class of Securities Common stock, $0.001 par value per share (e) CUSIP Number 16941T203 3 Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8). (e) An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E); (f) An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F); (g) A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G); (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). (k) A group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: 4 Item 4. Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned: 15,000,000 (b) Percent of class: 27.29% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: 15,000,000 (ii) Shared power to vote or to direct the vote: 0 (iii) Sole power to dispose or to direct the disposition of: 15,000,000 (iv) Shared power to dispose or to direct the disposition of: 0 Item 5. If this statement is being filed to report the fact that as of the date

View Full Filing

View this SC 13G filing on SEC EDGAR